Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Free Cash Flow (2016 - 2025)

United Therapeutics (UTHR) has disclosed Free Cash Flow for 17 consecutive years, with $173.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 31.91% to $173.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 3.69% year-over-year, with the annual reading at $1.0 billion for FY2025, 3.69% down from the prior year.
  • Free Cash Flow hit $173.3 million in Q4 2025 for United Therapeutics, down from $351.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $397.4 million in Q3 2023 to a low of -$44.9 million in Q4 2023.
  • Historically, Free Cash Flow has averaged $212.6 million across 5 years, with a median of $217.0 million in 2021.
  • Biggest five-year swings in Free Cash Flow: tumbled 121.08% in 2023 and later surged 666.82% in 2024.
  • Year by year, Free Cash Flow stood at $221.1 million in 2021, then dropped by 3.66% to $213.0 million in 2022, then crashed by 121.08% to -$44.9 million in 2023, then soared by 666.82% to $254.5 million in 2024, then crashed by 31.91% to $173.3 million in 2025.
  • Business Quant data shows Free Cash Flow for UTHR at $173.3 million in Q4 2025, $351.6 million in Q3 2025, and $129.5 million in Q2 2025.